AbbVie (ABBV)

206.60
-4.72 (-2.23%)
NYSE · Last Trade: May 3rd, 7:16 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close211.32
Open211.00
Bid205.67
Ask207.00
Day's Range205.57 - 211.00
52 Week Range176.57 - 244.81
Volume6,343,107
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.920 (3.35%)
1 Month Average Volume6,871,507

Chart

About AbbVie (ABBV)

AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More

News & Press Releases

The Best Stocks to Buy With $1,000 Right Nowfool.com
The timing is great for scooping up shares of these well-run companies.
Via The Motley Fool · May 3, 2026
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beatmarketbeat.com
Via MarketBeat · May 2, 2026
MarketBeat Week in Review – 04/27 - 05/01marketbeat.com
Via MarketBeat · May 2, 2026
Aqua Medical Spa Launches New Website to Showcase Aesthetic and Wellness Services in London, ON
London, ON - Aqua Medical Spa has launched a new website designed to enhance client engagement with its full range of aesthetic and wellness services. With a focus on user experience and accessibility, the website provides an updated platform for new and returning clients to explore treatments, learn about the spa’s philosophy, and easily schedule appointments. The launch underscores the commitment of this trusted Medical Spa in London to combining innovative care with convenience.
Via GetFeatured · May 1, 2026
AbbVie Inc (NYSE:ABBV) Beats Q1 Estimates and Raises Full-Year Profit Guidancechartmill.com
Via Chartmill · April 29, 2026
ABBV Q1 Deep Dive: Immunology and Neuroscience Growth, Raised Full-Year Outlook
Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-G...
Via StockStory · April 30, 2026
EDMP picks up Sonoco, and the position size is doing the talkingfool.com
Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%.
Via The Motley Fool · April 29, 2026
AbbVie (ABBV) Stock Trades Up, Here Is Why
What Happened? Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.5% in the afternoon session after the company reported first-quarter results that...
Via StockStory · April 29, 2026
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?marketbeat.com
Via MarketBeat · April 29, 2026
AbbVie (ABBV) Q1 2026 Earnings Transcriptfool.com
AbbVie (ABBV) Q1 2026 Earnings Transcript
Via The Motley Fool · April 29, 2026
AbbVie’s (NYSE:ABBV) Q1 CY2026 Sales Top Estimates
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q1 CY2026, with sales up 12.4% year on year to $15 billion. Its non-GAAP ...
Via StockStory · April 29, 2026
Should You Buy AbbVie Stock Hand Over Fist Before April 29?fool.com
Mind your investment horizon.
Via The Motley Fool · April 28, 2026
AbbVie (ABBV) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Wednesday before market hours. Here’s what to expect. AbbVie beat analysts...
Via StockStory · April 27, 2026
Is Bristol Myers Squibb the Best Bargain in Big Pharma?fool.com
This pharma stock is cheap for a reason.
Via The Motley Fool · April 27, 2026
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc...
Via StockStory · April 22, 2026
Should You Forget Pfizer and Buy This Pharma Stock Instead?fool.com
Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?
Via The Motley Fool · April 22, 2026
Growth in Non-Surgical Aesthetic Treatments Reported Across Tampa Bay Locations
Hermann Aesthetics and Wellness reports growing interest in non-surgical aesthetic treatments across Tampa, including Downtown, Westshore, and South Tampa, reflecting broader demand for flexible cosmetic and wellness options.
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopolyfool.com
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.
Via The Motley Fool · April 21, 2026
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyondfool.com
These stocks pay juicy dividends but also offer much more.
Via The Motley Fool · April 19, 2026
3 Stocks I Plan to Hold for the Next 20 Yearsfool.com
These stocks are keepers.
Via The Motley Fool · April 18, 2026
The Psychedelic Revolution in Mental Healthcarefool.com
Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and Reclaiming Your Life.
Via The Motley Fool · April 17, 2026
Why AbbVie Is a No-Brainer Stock to Buy on the Dipfool.com
The pharma giant is still a rock-solid dividend stock.
Via The Motley Fool · April 16, 2026
1 Value Stock Worth Your Attention and 2 That Underwhelm
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via StockStory · April 16, 2026
3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the Marketfool.com
These stocks pay between 3.3% and 6.3% and are backed by strong financials.
Via The Motley Fool · April 15, 2026
Could AbbVie Crash Lilly's Weight‑Loss Party?fool.com
AbbVie is making progress in this market, but it is still far behind the leader.
Via The Motley Fool · April 14, 2026